158 related articles for article (PubMed ID: 33915997)
1. Expression of
Müller CSL; Pföhler C; Wahl M; Bochen F; Körner S; Kühn JP; Bozzato A; Schick B; Linxweiler M
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915997
[No Abstract] [Full Text] [Related]
2. Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas.
Bochen F; Adisurya H; Wemmert S; Lerner C; Greiner M; Zimmermann R; Hasenfus A; Wagner M; Smola S; Pfuhl T; Bozzato A; Al Kadah B; Schick B; Linxweiler M
Oncotarget; 2017 Jan; 8(3):4922-4934. PubMed ID: 28002801
[TBL] [Abstract][Full Text] [Related]
3. Effect of the 3q26-coding oncogene
Radosa JC; Kasoha M; Schilz AC; Takacs ZF; Kaya A; Radosa MP; Linxweiler B; Linxweiler M; Bohle RM; Wagner M; Wagenpfeil G; Solomayer EF; Zimmermann JSM
Front Physiol; 2022; 13():1054508. PubMed ID: 36685175
[TBL] [Abstract][Full Text] [Related]
4. Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer.
Takacs FZ; Radosa JC; Linxweiler M; Kasoha M; Bohle RM; Bochen F; Unger C; Solomayer EF; Schick B; Juhasz-Böss I
Arch Gynecol Obstet; 2019 May; 299(5):1405-1413. PubMed ID: 30747329
[TBL] [Abstract][Full Text] [Related]
5. Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation.
Linxweiler M; Schneider M; Körner S; Knebel M; Brust LA; Braun FL; Wemmert S; Wagner M; Hecht M; Schick B; Kühn JP
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201525
[TBL] [Abstract][Full Text] [Related]
6. Expression of 3q oncogene
Müller CSL; Kreie L; Bochen F; Pfuhl T; Smola S; Gräber S; Vogt T; Schick B; Linxweiler M
Oncol Lett; 2019 Feb; 17(2):1768-1776. PubMed ID: 30675236
[TBL] [Abstract][Full Text] [Related]
7. Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer.
Linxweiler M; Linxweiler J; Barth M; Benedix J; Jung V; Kim YJ; Bohle RM; Zimmermann R; Greiner M
Am J Pathol; 2012 Feb; 180(2):473-83. PubMed ID: 22197383
[TBL] [Abstract][Full Text] [Related]
8. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
9. Antagonizing Sec62 function in intracellular Ca
Körner S; Pick T; Bochen F; Wemmert S; Körbel C; Menger MD; Cavalié A; Kühn JP; Schick B; Linxweiler M
Front Physiol; 2022; 13():880004. PubMed ID: 36045752
[TBL] [Abstract][Full Text] [Related]
10. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Piris A; Mihm MC; Hoang MP
Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
[TBL] [Abstract][Full Text] [Related]
11. The endoplasmic reticulum membrane protein Sec62 as potential therapeutic target in
Zimmermann JSM; Linxweiler J; Radosa JC; Linxweiler M; Zimmermann R
Front Physiol; 2022; 13():1014271. PubMed ID: 36262254
[TBL] [Abstract][Full Text] [Related]
12. Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma.
Wemmert S; Lindner Y; Linxweiler J; Wagenpfeil S; Bohle R; Niewald M; Schick B
Oncol Lett; 2016 Mar; 11(3):1661-1670. PubMed ID: 26998059
[TBL] [Abstract][Full Text] [Related]
13. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
15. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
16. Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
Dundr P; Simon K; Němejcová K; Bártů M; Tichá I; Michálková R; Jakša R; Věcková Z; Kodet O
Melanoma Res; 2019 Apr; 29(2):157-162. PubMed ID: 30422880
[TBL] [Abstract][Full Text] [Related]
17. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
18. Genetics of melanocytic nevi.
Roh MR; Eliades P; Gupta S; Tsao H
Pigment Cell Melanoma Res; 2015 Nov; 28(6):661-72. PubMed ID: 26300491
[TBL] [Abstract][Full Text] [Related]
19. Role of SEC62 in ER maintenance: A link with ER stress tolerance in SEC62-overexpressing tumors?
Bergmann TJ; Fumagalli F; Loi M; Molinari M
Mol Cell Oncol; 2017; 4(2):e1264351. PubMed ID: 28401179
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes.
Ko JS; Matharoo-Ball B; Billings SD; Thomson BJ; Tang JY; Sarin KY; Cai E; Kim J; Rock C; Kimbrell HZ; Flake DD; Warf MB; Nelson J; Davis T; Miller C; Rushton K; Hartman AR; Wenstrup RJ; Clarke LE
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1107-1113. PubMed ID: 28377414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
